<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> and <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, two DNA methyltransferase (DNMT) inhibitors, are the current standard of treatment for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> deacetylase (HDAC) inhibitors are also being tested against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Both drug classes synergize in their gene reactivating and anticancer activities </plain></SENT>
<SENT sid="3" pm="."><plain>The combination of hydralazine and valproate (Transkrip®), a DNMT and HDAC inhibitor, respectively), has been developed as epigenetic therapy under the drug repositioning concept </plain></SENT>
<SENT sid="4" pm="."><plain>To evaluate the clinical efficacy and safety of hydralazine and valproate against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, an open phase-II study for previously treated patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was conducted </plain></SENT>
<SENT sid="5" pm="."><plain>The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day </plain></SENT>
<SENT sid="6" pm="."><plain>Response was graded with International Working Group criteria </plain></SENT>
<SENT sid="7" pm="."><plain>Toxicity was evaluated by the Common <z:e sem="disease" ids="C0040524,C0032914" disease_type="Disease or Syndrome" abbrv="">Toxemia</z:e> Criteria-National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute version 3 scale </plain></SENT>
<SENT sid="8" pm="."><plain>From November 2007 to January 2010, 12 patients were included </plain></SENT>
<SENT sid="9" pm="."><plain>Median age±SD was 53±19.78 years (range, 23-79 years); median time from diagnosis to inclusion in the study was 7.9 months (range 2.6-36.1 months) </plain></SENT>
<SENT sid="10" pm="."><plain>Median of previous treatment was 2 (range, 1-6) </plain></SENT>
<SENT sid="11" pm="."><plain>Refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> was diagnosed in ten cases, and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in two </plain></SENT>
<SENT sid="12" pm="."><plain>Overall response was documented in six (50%) of 12 cases, including one CR, one PR, and four hematological improvements of the erythroid series </plain></SENT>
<SENT sid="13" pm="."><plain>Two patients (16.6%) progressed to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="35143">Hemoglobin</z:chebi> increased from 7.4 to 10.3 g/dL (in 13 weeks), neutrophils, from 1.1 to 2.0 (in 3 weeks), and platelets, from 66×10(9) to 72×10(9)/L (in 2 weeks) </plain></SENT>
<SENT sid="15" pm="."><plain>Transfusional requirements decreased from 2.3 to 0 U bi-monthly for red blood cells and from 0.5 to 0 U bi-monthly for platelets in responding patients </plain></SENT>
<SENT sid="16" pm="."><plain>Main toxicities were mild, including <z:hpo ids='HP_0001262'>somnolence</z:hpo> and <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="17" pm="."><plain>Preliminary results of this phase-II study suggest that the combination of hydralazine and valproate is a promising non-toxic and effective therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>